Embedded Files
The Life-Saving Therapies Network is committed to empowering patients, survivors and caregivers. The LSTN Academy is an extension of this commitment. It will provide patients and those advocating on behalf of patients with the tools, knowledge and insight into a variety of subjects including clinical practices, regulatory hurdles, health economics and experimental design. We hope that the information provided will broaden perspectives and tackle current and future challenges. Above all, we hope it will encourage you to challenge the status quo and advocate for better healthcare outcomes for patients with lethal disorders.
The Life-Saving Therapies Network is committed to empowering patients, survivors and caregivers. The LSTN Academy is an extension of this commitment. It will provide patients and those advocating on behalf of patients with the tools, knowledge and insight into a variety of subjects including clinical practices, regulatory hurdles, health economics and experimental design. We hope that the information provided will broaden perspectives and tackle current and future challenges. Above all, we hope it will encourage you to challenge the status quo and advocate for better healthcare outcomes for patients with lethal disorders.
Drug Access and Regulations
Drug Access and Regulations
Canada’s drug regulatory framework is anchored in the Food and Drugs Act and its associated regulations, which empower Health Canada’s Health Products and Food Branch to oversee the safety, efficacy, and quality of therapeutic products. This mandate covers a broad spectrum of products—from pharmaceuticals, biologics, and genetic therapies to medical devices, natural health products, and veterinary drugs. Every drug must undergo a rigorous scientific review by Health Canada scientists before it can be authorized for sale, ensuring that Canadians can trust the products available on the market.
The drug approval pathway in Canada begins with pre-clinical studies and moves through clinical trial authorization to formal product submission. Health Canada assesses each submission against strict criteria, issuing a Notice of Compliance once a product meets all safety and effectiveness standards. For drugs not yet approved, the Special Access Programme allows health care practitioners to request treatment options when conventional therapies have failed, are unsuitable, or unavailable, enabling patients with serious or life-threatening conditions to access investigational medicines under controlled circumstances.
Beyond market approval, Canada regulates controlled substances through the Controlled Drugs and Substances Act, which classifies and controls activities—sale, production, possession, and distribution—related to narcotics, psychotropics, and precursor chemicals. The Cannabis Act establishes a legal framework for cannabis, while the Tobacco and Vaping Products Act governs tobacco and vaping products. These domestic regulations operate in concert with international drug control treaties to protect public health and safety while facilitating legitimate medical and scientific uses of controlled substances.
For more in-depth information, please check out the videos below.
Clinical Understanding of Cancer and Therapies
Clinical Understanding of Cancer and Therapies
Canada has made significant strides in its clinical understanding of cancer through a combination of public health initiatives, academic research, and national cancer registries. Clinicians focus heavily on early detection strategies, risk assessment, and molecular profiling to better understand cancer progression and individual patient responses. Advances in genomic sequencing have enabled Canadian researchers to identify specific mutations and biomarkers associated with various cancer types—informing diagnosis and guiding personalized treatment plans.
In terms of therapy, Canada continues to adopt and develop cutting-edge treatments ranging from immunotherapy and targeted therapies to advanced radiation and surgical techniques. Institutions such as Princess Margaret Cancer Centre and BC Cancer are internationally recognized for pioneering work in areas like CAR T-cell therapy and precision oncology. Moreover, clinical trials across the country aim to evaluate not only the efficacy of new drugs but also how different demographic and genetic factors affect treatment outcomes—highlighting Canada's commitment to equity in care.
What sets Canada apart is its integrated and patient-focused healthcare system, supported by provincial cancer agencies like Cancer Care Ontario. The system encourages collaboration between primary care providers, oncologists, researchers, and patient support groups to deliver holistic treatment plans. Education and mental health resources are also prioritized, reflecting an understanding that cancer care goes beyond the physical disease. As a result, survivorship care and long-term quality of life are central themes in the evolving clinical landscape.
For more in-depth information, please check out the videos below.
Page updated
Google Sites
Report abuse